Brain Trust Accelerator Fund is a specialized venture fund based in Burlingame that focuses on technologies addressing neurological disease and brain health. The fund was built around the idea of translating promising science into clinical applications for patients with unmet neurological needs.

Its portfolio includes companies such as NeuroTherapia and Chase Therapeutics, reflecting activity across both therapeutics and brain-related medical technologies. The fund stands out for its disease-focused orientation and its emphasis on improving outcomes for people with neurological disorders.

Its geographic focus is primarily the United States. It is particularly relevant for neuro-focused founders seeking investors with a strong domain commitment rather than a generalist healthcare mandate.